Nonconvulsive seizure control in the intensive care unit

Area of Science:

• Critical Care Medicine
• Neurology
• Clinical Pharmacology

Background:

• Nonconvulsive seizures (NCS) affect up to 20% of comatose critically ill patients.
• Current treatment strategies for NCS often rely on data from convulsive status epilepticus (SE), potentially leading to overtreatment with sedating medications.
• The optimal urgency and choice of medications for NCS remain unclear, impacting patient outcomes and hospital stays.

Purpose of the Study:

• To review current understanding and evidence regarding the treatment of nonconvulsive seizures in comatose critically ill patients.
• To compare the efficacy and side effect profiles of different antiepileptic drugs (AEDs) for NCS.
• To guide clinical decision-making in the management of NCS.

Main Methods:

• Review of existing literature and clinical trial data on AEDs used for NCS.
• Comparison of sedating versus nonsedating AEDs based on available evidence.
• Evaluation of specific AEDs including valproic acid, lacosamide, phenytoin/fosphenytoin, and levetiracetam.

Main Results:

• Nonsedating AEDs are favored due to a superior side effect profile compared to sedating medications.
• Preliminary data suggests valproic acid and lacosamide may be more effective and better tolerated than phenytoin/fosphenytoin and levetiracetam for NCS.
• Limited data exists for other AEDs like topiramate and pregabalin, particularly those lacking intravenous formulations.

Conclusions:

• The choice of AED for NCS in comatose patients should consider efficacy and side effect profiles, favoring nonsedating options when possible.
• Valproic acid and lacosamide show promise as preferred agents, though further research is needed.
• Ongoing and completed clinical trials are expected to provide more definitive guidance on optimal NCS treatment strategies.